Quince acquires Orphai and raises $187M to advance LAM-001 pulmonary pipeline through Phase 2b trials in PH-ILD, BOS, and...

Oorja Bio raises $30M Series A to advance ORJ-001, a novel subcutaneous peptide targeting upstream epithelial dysfunction in idiopathic...

Jupiter Neurosciences (JUNS) just licensed ALA-002, a Novel Chemical Entity MDMA, for $100M+—here's why the NCE status matters more...

PharmAla licenses ALA-002 U.S. rights to Jupiter Neurosciences for $100M, with NCE-protected MDMA formulation advancing through regulatory pathway.

SERB acquires Idefirix European and MENA rights from Hansa for €115M, gaining exclusive access to a rare transplant immunosuppressant.

Oorja Bio launches with $30M Series A for IPF peptide ORJ-001, targeting β1 integrin to reverse established fibrosis ahead...

Quince acquires Orphai and raises $115M to advance LAM-001, an inhaled rapamycin formulation, through three rare lung disease trials...

Regeneron pays $50M upfront plus $75M equity for access to Parabilis' peptide platform designed to deliver intracellular payloads.

Roche's giredestrant lidERA data at ASCO 2026 targets early breast cancer across menopause status — and the $4.3B aromatase...

SERB acquires European rights to Idefirix from Hansa for €115M, with €110M upfront and €5M contingent on full EMA...